Pharmacist Moms Group^™

Shivang Joshi, MD, MPH, RPh, FAHS, discusses how Symbravo’s multi-mechanistic fixed-dose design may address gaps in acute migraine therapy for patients who do not respond to single-agent treatments.

Sam Klempner, MD, discusses early findings for the bispecific T-cell engager ASP2138, including monotherapy response, combination activity, and safety enhancements through subcutaneous dosing.

Panelists discuss how coordinated multidisciplinary care improves adherence to oral targeted therapy.

Panelists discuss practical strategies to overcome barriers to initiating and maintaining CDK4/6 inhibitor therapy.

This segment explains how ASCENT-04 assessed whether moving sacituzumab govitecan into the first-line setting with immunotherapy could improve outcomes for a population with historically limited options.

This segment summarizes the challenges of metastatic TNBC and highlights how current treatment decisions rely on biomarkers and evolving molecular profiling to guide a personalized therapeutic approach.

Discover how triple combination therapy for hypertension enhances cardiovascular health, as endorsed by the AHA and supported by pharmacists.

Diana Isaacs, PharmD, discusses evolving perceptions of obesity, the expanding role of pharmacotherapy, and how pharmacists can drive access, counseling, and long-term metabolic health.

Olezarsen effectively lowers triglycerides and enhances cardiovascular health, especially when combined with fibrates, benefiting pharmacists and patients alike.